We are proud to announce that several projects we supported have been awarded funding under DTIF Call 7. This latest round represents a significant vote of confidence in the quality and ambition of Irish innovation across multiple sectors.

The Disruptive Technologies Innovation Fund (DTIF) is Ireland's key funding mechanism for developing breakthrough technologies that can transform industries and create economic value. The fund supports projects that combine scientific excellence with commercial potential, backing Irish teams as they move from laboratory concepts to market-ready solutions. In a rapidly evolving global innovation landscape, DTIF has become essential to keeping Ireland competitive in deep tech and advanced manufacturing.

Three projects have already been awarded funding in Call 7. Now, the funding scheme has awarded €33.1 million to eight new projects. When combined with previous allocations, DTIF has now distributed a cumulative total of €455 million since its inception.

Among those winning funding are five projects supported by Myriad: DUOMAX, ECORE, ProVascTec, FutureLives, and PIONEER. Each addresses a genuine gap in their respective fields and combines technological innovation with strong commercial ambition.

Understanding What DTIF Backing Means

The DTIF fund assesses projects across four key criteria: the disruptive potential of the technology, scientific and technical excellence, expected impact on industry or society, and the strength of the collaboration within the consortium. This means an award is not simply financial support; it is recognition that independent expert panels believe your team has what it takes to succeed.

For the consortia winning in Call 7, the benefits are substantial. There is the obvious one of capital, which allows teams to de-risk their research and push toward commercial milestones. Beyond that, DTIF backing provides validation in the eyes of investors, partners, and customers. When a team can say their project has survived DTIF assessment, doors tend to open more easily. The fund also acts as a catalyst for bringing partners together across companies and universities, forcing the kind of structured collaboration that might otherwise take years to develop.

To date, 64% of DTIF allocations have gone to projects outside Dublin. This geographic distribution is deliberate and important. It spreads innovation activity and job creation across the regions, helping to build innovation capacity beyond the capital and preventing the concentration of opportunity in one place.

What the Five Winning Projects Do

DUOMAX addresses a difficult clinical problem. Some patients with failing tricuspid valves are unsuitable for conventional repair or replacement procedures. They may be elderly, high-risk, or have compromised right ventricular function. DUOMAX is a device tailored specifically for these complex cases.

The consortium, led by CroiValve and including BlueAcre, the Royal College of Surgeons, and Trinity College Dublin, expects the technology to extend treatment eligibility, reduce surgical risk, and improve quality of life for patients who currently have few options.

ECORE is a minimally invasive delivery system for targeted therapies in vascular disorders and cancer. The technology combines therapeutic and mechanical functions in a single device, allowing clinicians to deliver treatment with greater precision and reduced collateral damage.

The consortium partners are LaNua Medical, Integer Holdings, and University College Dublin.

ProVascTec takes a different approach to ischemic disease. The project uses cell therapy and regenerative medicine to stimulate and control angiogenesis, the formation of new microvasculature. Initial work focuses on Critical Limb Threatening Ischemia, a condition that can lead to amputation if untreated. The technology offers spatial and temporal control of growth, which addresses one of the key challenges in regenerative medicine.

The ProVascTec team includes Arrotek and University College Cork.

FutureLives shifts the focus from human health to agriculture and climate. The project aims to enhance nutrient use efficiency in farming, reduce greenhouse gas emissions, and build climate-resilient agricultural systems. It draws on advances in biotechnology, sensor technology, and the Internet of Things, with innovations including rumen technology and optimised nutrient uptake.

The consortium includes GlasPort Bio, GlasPort Rumen Tech, Agri-IOT, and the University of Galway. The potential impact is significant: lower emissions, reduced waste, and more sustainable farming practices.

PIONEER is a repositionable left atrial appendage occluder designed for high-risk atrial fibrillation patients not well served by current options. The engineering challenge lies in creating a device that can be precisely positioned and, if needed, repositioned after implantation.

The consortium brings together AuriGen Medical, Integer Holdings (through its Brivant and Aran Biomedical divisions), and Atlantic Technological University.

What This Means for Ireland's Innovation Ecosystem

These five projects demonstrate that Irish teams can compete at the frontier of disruptive technology development. They show that strong collaborations between industry, universities, and research institutes produce better outcomes than isolated efforts. And they illustrate that Ireland can generate the kind of deep-tech innovation that creates sustainable, high-value jobs.

DTIF emphasises SME participation, and these projects reflect that. Smaller companies and spin-outs are taking the lead on research, often in partnership with larger manufacturers and academic institutions. This model builds an innovation ecosystem where ideas developed in universities can be commercialised by agile teams, then scaled with support from established companies.

These projects also enhance Ireland's global reputation. When Irish teams produce breakthrough technologies in medtech, sustainability, and life sciences, it reinforces Ireland's position as a place where deep tech is developed and commercialised.

Looking Ahead

Evaluation of remaining Call 7 applications is ongoing, and the government has confirmed that a further DTIF call will be announced later this year. Future calls are likely to emphasise frontier technologies, green innovation, health-related breakthroughs, and digital infrastructure. The successful projects from Call 7, including the five we supported, will help shape those priorities and demonstrate what good collaboration and ambitious thinking can achieve.

Warm congratulations are due to the teams behind DUOMAX, ECORE, ProVascTec, FutureLives, and PIONEER. Securing DTIF funding requires sustained effort, rigorous thinking, and genuine belief in the potential of your technology. All of these consortia have demonstrated those qualities. We look forward to following their progress as they move toward commercialisation and market entry.

If you are working on a disruptive technology project or are interested in how DTIF funding might support your innovation journey, get in touch with our team. We can help teams understand how to position their work for funding success and how to build the collaborations that funders value.